Skip to main content
. Author manuscript; available in PMC: 2020 Feb 15.
Published in final edited form as: Clin Cancer Res. 2019 Jun 10;25(16):5038–5048. doi: 10.1158/1078-0432.CCR-18-1897

Figure 4.

Figure 4

Association of E17 mutations with outcomes in CBF AML. (A) DFS in CBF patients for KIT E17+ compared to KIT− patients; (B) RR in CBF patients for KIT E17+ compared to KIT− patients; (C) DFS for CBF patients treated on the GO-containing arm according to KIT E17 status, with the E17+ patients stratified by treatment arm of standard chemotherapy (No GO) compared to GO containing regimen (GO); (D) RR for the CBF patients treated on the GO-containing arm according to KIT E17 status, with the E17+ patients stratified by treatment arm of standard chemotherapy (No GO) compared to GO containing regimen (GO).